Boston/EndoTex carotid stent:
This article was originally published in Clinica
Executive Summary
The US FDA has approved for sale the NexStent carotid stent and monorail delivery system made by EndoTex Interventional Systems, a company that is due to be acquired by Boston Scientific. NexStent, for use in carotid artery disease patients for whom surgery is deemed too risky, is a laser-cut, nitinol stent with a rolled sheet design that enables one stent size to be adapted to multiple diameters in tapered or non-tapered vessel configurations. It has a closed-cell configuration design that increases lesion coverage and provides a smooth inner lumen to help facilitate delivery and retrieval of ancillary devices. It has been distributed exclusively by Boston outside the US since receiving European CE marking in 2005.